WO2023168062A3 - Nanoliposome c6-ceramide in combination with anti-ctla4 antibody improves anti-tumor immunity in hepatocellular cancer - Google Patents

Nanoliposome c6-ceramide in combination with anti-ctla4 antibody improves anti-tumor immunity in hepatocellular cancer Download PDF

Info

Publication number
WO2023168062A3
WO2023168062A3 PCT/US2023/014477 US2023014477W WO2023168062A3 WO 2023168062 A3 WO2023168062 A3 WO 2023168062A3 US 2023014477 W US2023014477 W US 2023014477W WO 2023168062 A3 WO2023168062 A3 WO 2023168062A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoliposome
hepatocellular cancer
ceramide
combination
tumor immunity
Prior art date
Application number
PCT/US2023/014477
Other languages
French (fr)
Other versions
WO2023168062A2 (en
Inventor
Mark Kester
Kevin F. STAVELEY-O'CARROLL
Guangfu LI
Original Assignee
The Curators Of The University Of Missouri
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Curators Of The University Of Missouri, University Of Virginia Patent Foundation filed Critical The Curators Of The University Of Missouri
Publication of WO2023168062A2 publication Critical patent/WO2023168062A2/en
Publication of WO2023168062A3 publication Critical patent/WO2023168062A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Hepatocellular cancer (HCC) is the most common primary hepatic malignancy and is the third-highest cause of cancer-related death. Surgical resection and liver transplantation are curative treatments for only a small number of early-stage patients. Disclosed are compositions and methods of treating hepatocellular cancer. The compositions include a combination therapy including nanoliposome C6-cerarnide and anticytotoxic T-lymphocyte antigen 4 antibody.
PCT/US2023/014477 2022-03-04 2023-03-03 Nanoliposome c6-ceramide in combination with anti-ctla4 antibody improves anti-tumor immunity in hepatocellular cancer WO2023168062A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316723P 2022-03-04 2022-03-04
US63/316,723 2022-03-04

Publications (2)

Publication Number Publication Date
WO2023168062A2 WO2023168062A2 (en) 2023-09-07
WO2023168062A3 true WO2023168062A3 (en) 2023-12-07

Family

ID=87884164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/014477 WO2023168062A2 (en) 2022-03-04 2023-03-03 Nanoliposome c6-ceramide in combination with anti-ctla4 antibody improves anti-tumor immunity in hepatocellular cancer

Country Status (1)

Country Link
WO (1) WO2023168062A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018046736A1 (en) * 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018222989A1 (en) * 2017-06-02 2018-12-06 The Penn State Research Foundation Ceramide nanoliposomes, compositions and methods of using for immunotherapy
US20190031756A1 (en) * 2016-02-02 2019-01-31 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190031756A1 (en) * 2016-02-02 2019-01-31 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2018046736A1 (en) * 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018222989A1 (en) * 2017-06-02 2018-12-06 The Penn State Research Foundation Ceramide nanoliposomes, compositions and methods of using for immunotherapy

Also Published As

Publication number Publication date
WO2023168062A2 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
Imachi et al. Skin metastasis from carcinoma of the uterine cervix
Göldel et al. Chemotherapy of invasive thymoma. A retrospective study of 22 cases
Kodama et al. Long‐term results of postoperative intrathoracic chemo‐thermotherapy for lung cancer with pleural dissemination
AR077241A1 (en) METHOD OF TREATMENT OF CANCER CONANTAGONIST DLL4 AND CHEMOTHERAPEUTIC AGENT
JP2007119493A (en) Immunotherapeutic method of treating cancerous disease by administration of gamma globulin
Sun The role of Chinese medicine in clinical oncology
WO2023168062A3 (en) Nanoliposome c6-ceramide in combination with anti-ctla4 antibody improves anti-tumor immunity in hepatocellular cancer
Frytak et al. Necrotic lung and bronchopleural fistula as complications of therapy in lung cancer
Wang et al. Port‑site metastasis as a primary complication following retroperitoneal laparoscopic radical resection of renal pelvis carcinoma or nephron‑sparing surgery: A report of three cases and review of the literature
Ntatsis et al. Ovarian cancer: 20-year experience with cytoreductive surgery and perioperative intraperitoneal chemotherapy
Choi et al. Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells
Jacobs et al. 5-year results of cisplatin and fluorouracil infusion in head and neck cancer
Agolli et al. Adenoid cystic carcinoma of Bartholin's gland receiving adjuvant radiation therapy: case report.
Camp et al. Combined liver and pancreas resection with biochemotherapy for metastatic ocular melanoma
Mohammad et al. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model
Raj et al. Laparoscopic management of pseudomyxoma peritonei secondary to adenocarcinoma of the appendix
Zylberberg et al. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary
FURUKAWA et al. Immunochemotherapy Prevents Human Colon Cancer
Khanna et al. Does bacillus Calmette-Guérin immunotherapy accelerate growth and cause metastatic spread of second primary malignancy?
Carney et al. Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer
Knowles et al. Synchronous primary tumors of the liver and gallbladder: case report and review of the literature
Bianchi et al. New trends in treatment of ovarian dysgerminoma (D)
Deraco et al. Intraperitoneal hyperthermic perfusion (IPHP)
Mielko et al. Treatment of peritoneal surface neoplasms with intraperitoneal chemotherapy in hyperthermia
Xu et al. Current Status and Progress of the Treatment of Limited-Disease Small Cell Lung Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23763967

Country of ref document: EP

Kind code of ref document: A2